You are here: Industry Insights > PharmaMar

News List

Jazz' small cell lung cancer therapy wins US green light pharmatimes
June 17, 2020
Jazz Pharmaceuticals and PharmaMar have announced US approval of Zepzelca (lurbinectedin) for the treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
PharmaMar Submits Trial of Aplidin for COVID-19 to Spanish Medicines Agency americanpharmaceuticalreview
April 07, 2020
PharmaMar has announced the APLICOV clinical trial protocol for Aplidin® (plitidepsin) was submitted to the Spanish Medicines and Healthcare Products Agency (AEMPS).
PharmaMar Reports Positive Results for Aplidin Against Coronavirus contractpharma
March 16, 2020
Therapeutic target of Aplidin (plitidepsin), which is EF1A, is key to the multiplication and spread of the virus.
UCB and PharmaMar breach ABPI Code of Practice pharmatimes
July 17, 2018
UCB and PharmaMar have been named in advertisements for breaching the Association of the British Pharmaceutical Industry’s Code of Practice.
PharmaMar, Chugai Execute Early Termination Agreement contractpharma
July 03, 2018
PharmaMar and Chugai Pharmaceutical Co., Ltd. have entered into a mutual early termination agreement for for the license
PharmaMar Discovers New Data on the Mechanism of Action of Plitidepsin in Tumor Cells biospace
April 18, 2018
PharmaMar (MCE: PHM) has presented during the AACR meeting (American Association for Cancer Research) in Chicago new data about how plitidepsin works on the tumor cells.
PharmaMar signs commercialisation and distribution agreement for Aplidin® pharmaasia
January 05, 2018
PharmaMar has announced a commercialisation and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian Authority.
PharmaMar Starts Quadruple Combination Study with Aplidin americanpharmaceuticalreview
August 10, 2017
PharmaMar announced the start of a multicenter quadruple combination clinical study with Aplidin (plitidepsina), along with other compounds for the treatment of multiple myeloma. The main objective of this study is to evaluate the recommended dose (RD),